Attenuation of epithelial-mesenchymal transition via SGLT2 inhibition and diabetic cataract suppression by dapagliflozin nanoparticles treatment
Life Sciences · 2023-10 · 330 · 122005
DOI: 10.1016/j.lfs.2023.122005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Sciences, 2023-10. Verfasst von Ying-Ying Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Kaohsiung Veterans General Hospital, Kaohsiung 81362, Taiwan; National Yang-Ming University, Taipei 11221, Taiwan. Hauptthemen laut MEDLINE: Cataract, Diabetes Complications, Epithelial-Mesenchymal Transition, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council, National Scientific and Technical Research Council, Kaohsiung Veterans General Hospital.
Abstract (Originalsprache)
AIMS: Chronic hyperglycemia triggers overproduction of AKR1B1 (aldo-keto reductase family 1 member B) and receptor for advanced glycation end product (RAGE), which causes epithelial-mesenchymal transition (EMT) in the lens epithelial cells (LECs) of diabetic mellitus (DM) cataracts. However, it is unclear whether EMT in LECs is related to abnormal increase of SGLT2. Sodium glucose cotransporter 2 (SGLT2) inhibitor, also known as dapagliflozin (Dapa) can be used to treat diabetes. Here, we examined how Dapa or nano eye-drops (DapaN) reduce EMT in LECs of DM cataracts. The nano eye-drop provides an ophthalmic treatment that suppressed diabetic cataract progression and improved potency with reduced side effects. MAIN METHODS: SD rats were injected with streptozocin (STZ) (65 mg/kg, ip), nano-Dapa drops (0.456 mg/10 ml/eye) or Dapa (1.2 mg/kg/day) treatment for 6-12 weeks. Immunofluorescence staining was used for protein quantification of RAGE, SGLT2, N-cadherin and E-cadherin in the LECs of rats. KEY FINDINGS: In this study, Dapa applies nanotechnology-based delivery system and it contains polyvinylpyrrolidone (PVP) and HPBCD. Dapa showed therapeutic effect on DM cataracts, wherein it targeted EMT biomarker, E-cadherin. The nano-Dapa drops or oral Dapa inhibited SGLT2, suppressed AKR1B1 expression, decreased AcSOD2- and RAGE-induced EMT in diabetic cataracts. Our findings suggest that nanotechnology-based Dapa eye drops (Dapa-PVP-HPBCD) can effectively improve solubility of Dapa in aqueous solution. SIGNIFICANCE: Taken together, results suggest that the SGLT2-mediated DM cataract therapy may involve the AKR1B1-RAGE-AcSOD2-EMT pathway. The nano eye drops and Dapa show potential beneficial effects for cataract prevention. This study conveys new insights into cataract treatment and supplementation of nano-Dapa drops shows promising result in preventing diabetic cataracts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Kaohsiung Veterans General Hospital, Kaohsiung 81362, Taiwan; National Yang-Ming University, Taipei 11221, Taiwan.
- Department of Materials and Optoelectronic Science, National Sun Yat-sen University, Kaohsiung 80424, Taiwan.
- Department of Medical Education and Research, Kaohsiung Veterans General Hospital, Kaohsiung 81362, Taiwan; Institute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung 80424, Taiwan.
- Department of Internal Medicine, Division of Cardiology, Kaohsiung Veterans General Hospital, Kaohsiung 81362, Taiwan.
- Department of Anesthesiology, Kaohsiung Veterans General Hospital, Kaohsiung 81362, Taiwan.
- Department of Medical Education and Research, Kaohsiung Veterans General Hospital, Kaohsiung 81362, Taiwan; Institute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung 80424, Taiwan. Electronic address:…
Förderung
- National Science and Technology Council
- National Scientific and Technical Research Council
- Kaohsiung Veterans General Hospital
Zitieren
APA
Chen, Y. Y., Chen, C. K., Wu, T. T., Ho, C. Y., Yeh, T. C., Sun, G. C., Tseng, C. J., & Cheng, P. W. (2023). Attenuation of epithelial-mesenchymal transition via SGLT2 inhibition and diabetic cataract suppression by dapagliflozin nanoparticles treatment. Life Sciences, 330, 122005. https://doi.org/10.1016/j.lfs.2023.122005
Vancouver
Chen YY, Chen CK, Wu TT, Ho CY, Yeh TC, Sun GC, et al. Attenuation of epithelial-mesenchymal transition via SGLT2 inhibition and diabetic cataract suppression by dapagliflozin nanoparticles treatment. Life Sciences. 2023;330:122005. doi:10.1016/j.lfs.2023.122005
BibTeX
@article{Chen2023,
author = {Chen, Ying-Ying and Chen, Chih-Kuang and Wu, Tsung-Tien and Ho, Chiu-Yi and Yeh, Tung-Chen and Sun, Gwo-Ching and Tseng, Ching-Jiunn and Cheng, Pei-Wen},
title = {Attenuation of epithelial-mesenchymal transition via SGLT2 inhibition and diabetic cataract suppression by dapagliflozin nanoparticles treatment},
journal = {Life Sciences},
year = {2023},
volume = {330},
pages = {122005},
doi = {10.1016/j.lfs.2023.122005}
}
EUVIMED